US health plans sue Aventis and Andrx
A group of US Blue Cross/Blue Shield health insurance plans have broughta lawsuit against Aventis and Andrx, claiming that these manufacturers conspired to keep Cartia TX, Andrx' generic version of Aventis' hypertension and angina drug Cardizem (diltiazem), off the market and unavailable to their customers and members.
The suit, which the plaintiffs describe as "multimillion," has been launched by the Blue Cross/Blue Shield plans of Massachusetts, Michigan and Minnesota, plus Excellus Health Plan, which represents three of the Blues' plans operating in New York. In May, the Attorneys General of 16 US states introduced a similar lawsuit against the companies in the US District Court in Detroit, Michigan, claiming $100 million in restitution in addiion to civil damages and penalties on behalf of the 16 states' consumers (Marketletter May 21).
Praise for Michigan AG
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze